Equillium (EQ) vs ImmuCell (ICCC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
ImmuCell (ICCC) has outperformed Equillium (EQ) over the past year, gaining 48.0% versus a loss of 2.0%. Over five years, ICCC leads with a +5.1% price change compared with -75.6% for EQ. Equillium is the larger company by market cap ($91.3 million vs $88.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EQ | ICCC |
|---|---|---|
| Share price | $1.44 | $9.75 |
| Market cap | $91.31M | $88.55M |
| 1-day change | +3.60% | +0.62% |
| YTD return | -7.10% | +58.54% |
| 1-year return | -2.04% | +47.95% |
| 5-year return | -75.63% | +5.06% |
| P/E ratio (TTM) | — | 139.29 |
| EPS (TTM) | $-0.14 | $0.07 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.54 | $12.10 |
| 52-week low | $0.76 | $4.52 |
| Distance from 52-week high | -59.32% | -19.42% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +494.44% | — |
| Average volume | 583.72K | 22.20K |
| Shares outstanding | 63.41M | 9.08M |
| Employees | 14 | 73 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ICCC has outperformed EQ by 50.0 percentage points over the past year.
About Equillium
EQ stock →Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinical-stage for the treatment of ulcerative colitis and lung inflammation diseases.
Healthcare · Biotechnology · 14 employees
About ImmuCell
ICCC stock →ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that improves the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments, Scours and Mastitis.
Healthcare · Biotechnology · 73 employees
EQ vs ICCC FAQ
Which is bigger, Equillium or ImmuCell?
Equillium (EQ) is larger, with a market capitalization of $91.31M compared with $88.55M for ImmuCell (ICCC).
Which stock has performed better over the past year, EQ or ICCC?
ICCC returned +47.95% over the past 12 months, compared with -2.04% for EQ (price return, excluding dividends). Past performance does not predict future results.
Are Equillium and ImmuCell in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.